Co-repression of Yap1 and Sox9 Abrogates Established Cholangiocarcinoma by Eliminating Transcriptional Compensation

Key Points

• Cholangiocarcinoma is effectively eliminated by co-targeting Yap1 and Sox9, enhancing therapeutic potential.
• Results indicate that this co-targeting strategy addresses resistance to YAP1 inhibition, improving treatment efficacy.
• Analysis reveals an adaptive resistance mechanism that may apply to other cancers, extending implications for therapy.
• Findings support the strategy's broader application in advanced malignancies, highlighting the need for further research.